Sacituzumab Govitecan (SG) is an antibody-drug conjugate that has demonstrated efficacy in patients with TROP-2 expressing epithelial cancers. In a xenograft model of intracranial breast cancer, SG inhibited tumor growth and increased mouse survival. We conducted a prospective window-of-opportunity ...
Sacituzumab Govitecan (SG) is an antibody-drug conjugate that has demonstrated efficacy in patients with TROP-2 expressing epithelial cancers. In a xenograft model of intracranial breast cancer, SG inhibited tumor growth and increased mouse survival. We
SETHY is the first clinical trial with antibody-drug conjugates in thyroid cancer.Methods:The SETHY trial is a single-arm, multicohort, prospective, phase 2 trial of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid cancer being recruited in 10 ...
Sacituzumab govitecan is a targeted antibody-drug conjugate that may be used to treat adults with the following cancers that have spread (metastasized) or cannot be removed by surgery: triple-negative breast cancer, hormone receptor-positive and human ep
hRS7-SN38 antibody drug conjugate、Isactuzumab govitecan、Sacituzumab Govitecan + [10] 靶点 TOP1 x Trop-2 作用机制 TOP1抑制剂(DNA拓扑异构酶I抑制剂)、Trop-2抑制剂(肿瘤相关钙信号传感器2抑制剂) 治疗领域 肿瘤皮肤和肌肉骨骼疾病呼吸系统疾病+ [7] ...
SETHY is the first clinical trial with antibody-drug conjugates in thyroid cancer.Methods:The SETHY trial is a single-arm, multicohort, prospective, phase 2 trial of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid cancer being recruited in 10 ...
Click to learn more about TRODELVY® (sacituzumab govitecan-hziy). See full Prescribing Information, including BOXED WARNING.
“TROPiCS-04 showed that sacituzumab govitecan is active in advanced urothelial carcinoma but did not demonstrate significant improvement of physician’s choice of treatment,” Petros Grivas, MD, PhD, in the Department of Medicine in the Division of Hematology/Oncology at the University...
Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the ph
Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received acc...